Nabla Bio's latest AI model update generates de novo antibodies for GPCRs with therapeutic-grade properties within a few ...

The French biotechnology firm aims to develop therapies for various neurological conditions using its non-replicating HSV-1 vector technology.

Study in mice found transient microglial depletion, or chemokine receptor blockade, resolved immunotherapy-related cognitive impairment.

HHS Secretary Robert F. Kennedy Jr. and biopharmas will negotiate drug prices individually. Kennedy could "propose a rulemaking plan to impose MFN pricing" if no “significant” progress has been made.

The project could eventually add more than 400 manufacturing jobs and over 1,500 construction jobs during site development.